Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451160 | 1.00 | DGAT1 (0.41) | DGAT1GRIN2BGRIN1CYP1A2CYP2C9 | |
| SCHEMBL30040817 | 0.84 | GRIN2B (0.37) | DGAT1GRIN2BGRIN1CYP1A2CYP2C9 | |
| SCHEMBL112610 | 0.80 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL1417507 | 0.79 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL30475587 | 0.78 | HTR7 (0.42) | DGAT1 | |
| SCHEMBL8252347 | 0.78 | HTR7 (0.42) | DGAT1 | |
| SCHEMBL23716649 | 0.77 | DGAT1 (0.34) | DGAT1GRIN2B | |
| SCHEMBL2611088 | 0.77 | MET (0.47) | DGAT1 | |
| SCHEMBL17697674 | 0.77 | DGAT1 (0.40) | DGAT1GRIN2BGRIN1 | |
| SCHEMBL10329164 | 0.77 | RPS6KA5 (0.41) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019198692-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2019-10-17 | — | — | WO | disclosed |
| US-10428057-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190092764-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-28 | — | — | US | disclosed |
| US-10093664-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180186781-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-05 | — | — | US | disclosed |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2615918-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037298-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428057-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | CLK1, MAP3K12, CLK2 | DGAT1 2511/4885GRIN2B 1001/4885GRIN1 552/4885 |
| US-20180186781-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | DGAT1 2511/4885GRIN2B 1001/4885GRIN1 552/4885 |
| US-10093664-B2 | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | CLK1, MAP3K12, CLK2 | DGAT1 2511/4885GRIN2B 1001/4885GRIN1 552/4885 |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | DGAT1 38/4885GRIN2B 4351/4885GRIN1 3593/4885 |
| US-20190092764-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | DGAT1 2511/4885GRIN2B 1001/4885GRIN1 552/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | DGAT1 4461/4885GRIN2B 647/4885GRIN1 961/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | DGAT1 4461/4885GRIN2B 647/4885GRIN1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.